Arbutus Biopharma Corp. (ABUS)

4.38
NASDAQ : Health Technology
Prev Close 4.39
Day Low/High 4.33 / 4.59
52 Wk Low/High 4.01 / 12.60
Avg Volume 375.50K
Exchange NASDAQ
Shares Outstanding 55.50M
Market Cap 255.30M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Arbutus Biopharma (ABUS)

Oversold Conditions For Arbutus Biopharma (ABUS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ABUS Makes Notable Cross Below Critical Moving Average

ABUS Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Arbutus Biopharma Corp crossed below their 200 day moving average of $7.08, changing hands as low as $6.82 per share. Arbutus Biopharma Corp shares are currently trading off about 20.6% on the day.

ABUS Crosses Above Average Analyst Target

ABUS Crosses Above Average Analyst Target

In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $9.88, changing hands for $10.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arbutus Biopharma Reaches Analyst Target Price

Arbutus Biopharma Reaches Analyst Target Price

In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $7.75, changing hands for $7.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting ABUS Put And Call Options For August 17th

Interesting ABUS Put And Call Options For August 17th

Investors in Arbutus Biopharma Corp saw new options become available this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABUS options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Arbutus Announces Topline Results For ARB-1467 Phase II Cohort 4

Arbutus Announces Topline Results For ARB-1467 Phase II Cohort 4

Detailed Data to be Presented at AASLD in October

ABUS Crosses Above Average Analyst Target

ABUS Crosses Above Average Analyst Target

In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $6.62, changing hands for $6.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: E+ (Sell)